ClinicalTrials.gg
RecruitingNCT04507997Updated Apr 3, 2025

Angelman Syndrome Natural History Study

An observational study in Angelman Syndrome, sponsored by Boston Children's Hospital. Recruiting at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.

Started
2018
with 3 others
Observational
9 of 33
2 open now
Registered
20th of 33
by date
Lead sponsor
3 of 33
Boston Children's Hospital

Among the 33 studies in Angelman Syndrome with a site in United States, this one is one of 4 that started in 2018, is one of 9 observational ones, and was the 20th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Angelman Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.

Read the detailed description

The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and obtain Angelman-specific norms for outcome measures that can be used in clinical trials, ultimately improving the care of individuals with Angelman syndrome.

03

Conditions studied

  • Angelman Syndrome

Browse trials for

Keywords

  • Angelman syndrome
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All individuals with a molecular diagnosis of Angelman syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Molecular diagnosis of Angelman syndrome

Exclusion criteria

Exclusion Criteria:

  • Presence of another condition, unrelated to Angelman syndrome, that affects neurodevelopment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Medical History

    Includes various medical complications, including seizure history

    Time frame: Through study completion, an average of 1 year

  2. Vineland Adaptive Behavior Scales, 3rd edition

    Developmental and Adaptive skills

    Time frame: Through study completion, an average of 1 year

  3. Bayley Scales of Infant and Toddler Development, 4th edition

    Developmental skills

    Time frame: Through study completion, an average of 1 year

  4. Observer-Reported Communication Ability (ORCA) Measure

    Communication skills

    Time frame: Through study completion, an average of 1 year

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Apr 2031, 152 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 11, 2020
StartActual
Aug 1, 2018
Primary completionEst.
Apr 2031
CompletionEst.
Apr 2031
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04507997
Collaborators
University of California, San Diego, Angelman Syndrome Biomarker & Outcome Measure Consortium (A-BOM), Food and Drug Administration (FDA), Angelman Syndrome Foundation Canada, Foundation for Angelman Syndrome Therapeutics Canada, Foundation for Angelman Syndrome Therapeutics, Angelman Syndrome Foundation, Inc.
Responsible party
Wen-Hann Tan (Attending Physician in Genetics, Boston Children's Hospital) — Principal investigator
First posted
Aug 11, 2020
Start date
Aug 1, 2018
Primary completion
Apr 2031 (estimated)
Completion
Apr 2031 (estimated)
Last update
Apr 3, 2025

Study contacts

Wen-Hann Tan, BMBS
Contact
wen-hann.tan@childrens.harvard.edu
617-355 6394
Batsheva Friedman, MA
Contact
Batsheva.Friedman@childrens.harvard.edu
617-355-2030
Wen-Hann Tan, BMBS
study chair · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion